Episode
For Oncology Nurses: Oral Selective Estrogen Receptor Degraders in Breast Cancer — Proceedings from the 2026 Annual ONS Congress
- Podcast
- Breast Cancer Update
- Published
- Aug 18, 2026
- Duration seconds
- 5087
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/for-oncology-nurses-oral-selective-estrogen-receptor-degraders-in-breast-cancer-proceedings-from-the-2026-annual-ons-congress/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/breast-cancer-update-757579/for-oncology-nurses-oral-selective-estrogen-receptor-degraders-in-breast-cancer-proceedings-from-the-2026-annual-ons-congress.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Featuring perspectives from Ms Blanca Ledezma, Dr Marissa Marti-Smith, Dr Heather McArthur and Dr Ruth M O'Regan, moderated by Dr McArthur, including the following topics: Introduction (0:00) Current Clinical Role of Oral Selective Estrogen Receptor Degraders (SERDs) in HR-Positive Metastatic Breast Cancer (3:37) Practical Considerations with Oral SERDs (15:42) Potential Role of Combination Approaches with Oral SERDs (26:31) Gastrointestinal Adverse Events Documented with Oral SERDs (38:17) Potential Role of Early Therapeutic Switching After Detection of an Emergent ESR1 Mutation (46:51) Other Class-Effect Toxicities Associated with Oral SERDs (1:00:53) Emerging Utility of Adjuvant Oral SERDs (1:10:16) Unique Toxicities Associated with 1 or More Oral SERDs (1:19:17) CME information and select publications